Melphalan Hydrochloride
Sponsors
AstraZeneca AB, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University of Washington, Children's Oncology Group, City of Hope Medical Center
Conditions
Acute LeukemiaAcute Myeloid Leukemia in RemissionAdult Acute Lymphoblastic Leukemia in Complete RemissionBlasts 10 Percent or More of Bone Marrow Nucleated CellsChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaChronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Myelogenous Leukemia, BCR-ABL1 Positive in RemissionChronic Myelomonocytic Leukemia in Remission
Phase 1
Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).
CompletedNCT01688401
Start: 2013-03-08End: 2018-11-26Updated: 2019-03-28
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Active, not recruitingNCT03192397
Start: 2017-08-09End: 2027-05-21Updated: 2026-04-14
Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation
CompletedNCT03417284
Start: 2019-10-09End: 2024-07-18Updated: 2025-05-01
Phase 2
Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma
TerminatedNCT01293539
Start: 2011-03-31End: 2016-08-31Updated: 2018-11-27
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
CompletedNCT02756572
Start: 2016-09-22End: 2020-07-01Updated: 2021-11-08
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
CompletedNCT03128359
Start: 2017-05-30End: 2021-09-15Updated: 2024-01-09
Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant
WithdrawnNCT03328936
Start: 2018-09-01End: 2021-03-31Updated: 2020-02-21
Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
RecruitingNCT03126916
Start: 2018-05-14End: 2030-09-30Target: 750Updated: 2026-08-25
A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment with AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible (TE NDMM) (DURGA-6)
Not yet recruitingCTIS2026-525367-40-00
Target: 42Updated: 2026-10-06